Highlights in Medicinal Chemistry VI

Synopsis

This meeting aims to showcase aspects of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.

---

Attendees

This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.

---

Confirmed speakers

Dr Anna Barnard, Imperial College 
Professor Alessio Ciulli, University of Dundee
Dr Anders Johansson, AstraZeneca
Professor Mike Waring, Newcastle University

---

Programme

The programme will be confirmed in due course.


SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.

---

Sponsorship and exhibition information

For further information and prices, please email conferences@soci.org.

---

Call for oral abstracts

Abstracts for focussed 20-minute talks with contributions from the whole field of medicinal chemistry are now invited: please submit a one-page abstract to conferences@soci.org
by Friday 27 March 2026, with “Highlights VI – short talk abstract” in the subject line. An Abstract_Template can be downloaded

---

Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

---

Venue and Contact

---

Booking Process/Deadlines

Booking terms and conditions

---

CPD Info

All delegates attending this meeting are able to claim CPD points.

---

Organising committee

Dr Nicola Chessum, Boehringer Ingelheim RCV GmbH & Co KG
Dr Helen Horsley, UCB
Dr Joanne Pinder, Vertex Pharmaceuticals (Europe) Ltd
Dr Hugh Tawell, Domainex

---